UPDATE: Barclays Downgrades Symetra Financial (SYA) to Underweight; Elevated Sensitivity to Low Interest Rates
Get Alerts SYA Hot Sheet
Price: $32.02 --0%
Rating Summary:
0 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 19
Rating Summary:
0 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 19
Join SI Premium – FREE
(Updated - July 2, 2012 1:55 PM EDT)
Barclays downgraded Symetra Financial (NYSE: SYA) from Equalweight to Underweight. PT lowered from $13 to $10.
Analyst, Jay Gelb, said, "We downgrade SYA to Underweight reflecting elevated sensitivity to low interest rates. Valuations is currently low at 0.70x BV ex-AOCI, respectively. However, we expect valuations to remain compressed because roughly 70% of SYA's earnings earnings are interest-rate sensitive. Our top Life Insurance picks (MetLife (NYSE: MET) and AFLAC (NYSE: AFL)) appear to have less sensitivity to falling interest rates."
For an analyst ratings summary and ratings history on Symetra Financial click here. For more ratings news on Symetra Financial click here.
Shares of Symetra Financial closed at $12.62 yesterday.
Barclays downgraded Symetra Financial (NYSE: SYA) from Equalweight to Underweight. PT lowered from $13 to $10.
Analyst, Jay Gelb, said, "We downgrade SYA to Underweight reflecting elevated sensitivity to low interest rates. Valuations is currently low at 0.70x BV ex-AOCI, respectively. However, we expect valuations to remain compressed because roughly 70% of SYA's earnings earnings are interest-rate sensitive. Our top Life Insurance picks (MetLife (NYSE: MET) and AFLAC (NYSE: AFL)) appear to have less sensitivity to falling interest rates."
For an analyst ratings summary and ratings history on Symetra Financial click here. For more ratings news on Symetra Financial click here.
Shares of Symetra Financial closed at $12.62 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- L3Harris CEO steps down amid conduct review, shares drop
- Onemeta reports 500% usage rise and $2.4M cash flow in H1 2026
- Evaxion adds brain cancer vaccine program, drops EVX-03
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Barclays, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share